First, that the company's Copaxone multiple sclerosis drug was threatened by a new drug candidate (BG-12) from Biogen Idec ( NAS: BIIB ). Second, a more immediate threat came from generic versions of Copaxone that Novartis ( NYS: NVS ) and Mylan ( NYS: MYL ) wish to sell. A modest proposal But if you ask Deutsche Bank, the rise of generic drugs relative to their brand-name counterparts is the furthest thing from a bad thing for Teva, which Deutsche argues is now "the world's largest generic drug company." Deutsche praises the company for demonstrating superior operational execution and is particularly impressed with Teva's "successful track record of p-IV challenges." In short, if anyone knows how to deal with a generic threat, it's probably Teva -- whose claim to fame is its skill at finding and poking holes in the weak points of other companies' patent protections.